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ABSTRACT

Objective: several studies indicate increased prevalence of metabolic syndrome (MetS) among patients with psychiatric disorders as well as among individuals with gender dysphoria (GD) treated by cross-sex hormonal treatment. However, the MetS prevalence among hormone treated GD individuals suffering from psychiatric problems has not been detected.
Methods: from a sample of 146 GD patients we selected 122 metabolically healthy individuals in order to investigate the prevalence of MetS after the beginning of the cross-sex hormonal treatment in a 2 year follow-up assessment. Furthermore, we assessed differences in MetS prevalence between hormone treated GD patients with and without concomitant psychiatric problems. 
Results: when treated with hormone therapy, GD patients reported changes in several parameters which are clustered in MetS, with statistically signiﬁcant differences compared to baseline. Glyco-insulinemic alterations were more pronounced in male to female patients (MtFs). Instead, weight gain, waist circumference increase, blood pressure increase, and lipid alterations were similar in MtFs and female to male patients (FtMs). 14.8% of the sample at year 1 and 17.2% at year 2 developed MetS. Among patients with concomitant psychiatric problems, 50% at year 1 and 55% at year 2 developed Mets against 8% at year 1 and 10% at year 2 of patients without concomitant psychiatric problems. 




























The first formalized definition of the metabolic syndrome (MetS) was proposed in 1998 by the World Health Organization (WHO), considering insulin resistance as the major underlying risk factor necessary for diagnosis [1]. MetS has gradually evolved over time with progressively changing definitions, but the core disturbances, consisting of glucose intolerance (hyperinsulinaemia, insulin resistance), obesity (especially a visceral localization of body fat), hypertension (blood pressure  ≥ 140/90 mmHg), and dyslipidemia [high fasting triglycerides (TG), Low High Density Lipoprotein-Cholesterol (HDL-C), small and dense Low Density Lipoprotein-Cholesterol (LDL-C)] remain the cornerstone of all diagnostic criteria. All these features predispose the affected individual to an increased risk of cardiovascular disease (CVD) [2-4]. 
Persons with gender dysphoria (GD) are preoccupied with their wish to live as members of the other gender and experience an incongruence between their assigned gender and their experienced gender 5]Individuals with GD intensely desire to adopt the social role of the other sex or to acquire the physical appearance of the other sex through cross-sex hormonal treatment and sex reassignment surgery [5]. Men seeking transition to the female sex (MtFs) generally use oestrogen and antiandrogens (cyproterone acetate, spironolactone). Women seeking transition to the male sex (FtMs) generally use testosterone. The complexity of this treatment is in balancing psychological needs of patients and adverse effects. In fact, sex steroid hormones have been shown to play an important role in the appearance and development of MetS [6]. Studies on cross-sex hormones administration and sex-appropriate sex hormones administration in healthy subjects suggest that oestrogen and testosterone directly affect glucose metabolism, inducing insulin resistance, and induce dyslipidemia and abdominal/visceral fat increase [7-11]. Consistently, studies indicate that sex hormones use in GD may be associated with potential adverse effects such as glyco-insulinemic metabolism disorders, atherosclerosis, dyslipidemia and CVD [12-15]. In particular, individuals with GD, especially MtFs, may experience decreased insulin sensivity because of hormonal treatment [12, 16, 17]. Studies on lipid metabolism report an increased atherogenic profile, even during the first year of hormonal treatment [14, 15, 18-20], also indicating an association between the worsening of lipid parameters and the duration of hormone therapy, both in MtFs and FtMs [15]. Moreover, some studies report hypertension, weight gain and increased prevalence of type 2 diabetes after the beginning of hormone therapy [17, 21-24]. Finally, recent studies suggest a higher prevalence of myocardial infarction, cerebrovascular disease, venous thrombosis and an independent threefold increased risk of cardiovascular death in hormone treated MtFs, with some cases of venous thrombosis and/or pulmonary embolism during the first year of treatment [23-25]. In summary, many of the cardiovascular risk factors clustered in MetS are known to be affected by sex steroids administration in individuals with GD [17]. 
Recently, research has focused on medical co-morbidities in psychiatric disorders. MetS and CVD have emerged as a major cause of mortality in psychosis and affective disorders [26, 27], suggesting the importance of assessing cardiovascular risk in patients with psychiatric disorders. The mechanism underlying increased prevalence of MetS among patients with psychiatric disorders is not well understood. For both psychosis and depression, a number of explanations have been proposed, including lifestyle and dietary habits (i.e. sedentary behavior, sleep dysregulation, increased appetite) [28, 29], alterations of the hypothalamic pituitary-adrenal axis (HPA) [30, 31], vulnerability to a genotypic peculiar form of MetS [32-35] and direct action of antidepressant and antipsychotic drugs on lipid and carbohydrate metabolism [36-41]. 
Based on previous research and on our clinical experience, we hypothesized that patients with GD suffering from psychiatric disorders may have metabolic alterations, which could then further be worsened by the subsequent administration of cross-sex hormonal treatment. To our knowledge only one study has comprehensively investigated hormonal treatment induced MetS in a small group of metabolically healthy individuals with GD [17]. In addition, no previous study has investigated the role of concomitant psychiatric problems in the development of MetS in hormone treated  GD patients. 
















Study design and sample 
This is a 2 year follow-up study and was conducted at the Gender Identity Unit of the Bari University Psychiatric Department as part of a larger research on gender dysphoria patients’ psychobiological and mental distress [42, 43, 44]. A consecutive series of 146 patients was evaluated for GD from 2008 to 2013. Each patient has been visited by 2 psychiatrists with a special interest in this topic. Each patient has received psychological counseling and has been interviewed according to the semi-structured interview SCID I for psychiatric disorders. All participants met diagnostics criteria for gender identity disorder in adults according to DSM-IV-TR [45]. 
Clinical history was obtained from all subjects, including age, sex, personal and family medical history, intake of drugs, smoking and alcohol consumption, levels of physical exercise, previous history of high blood pressure or diabetes, and symptoms of coronary heart disease, ischemic stroke, or peripheral vascular disease. The following inclusion criteria were used in this study: fasting blood glucose (FG) <100 mg/dl (5.6 mmol/l), triglycerides (TG) < 150 mg/dl (1.7 mmol/l), total cholesterol (TC) < 240 mg/dl (6.2 mmol/l), body mass index (BMI) < 25 kg/m2; waist circumference < 102 cm for men and < 88 cm for women (according to the biological sex), according to the American Diabetes Association (ADA) criteria for MetS [4]; general analytical evaluation (hepatic, renal, and thyroid function, complete blood count, uric acid, and standard urine analysis) within normal limits; no use of medical/recreational drugs for six months prior to the study; alcohol consumption < 35 g per day; physical activity habits stable for 3 months preceding the enrollment. The following exclusion criteria were used in this study: hypertension (blood pressure ≥ 140/90 mmHg); consumption of a hypocaloric diet; weight gain or loss > 10% in the 3 months preceding the study; presence of any neurologic or previous treated psychiatric pathology; presence of any endocrinological or intersexual pathology (as diagnosed by the endocrinologist, and accompanied by hematologic and chromosome profile evaluations). 
After clinical screening (medical history, physical examination, and laboratory tests), only healthy subjects with inclusion criteria were enrolled into the study. A total of 122 subjects 79 (65%) MtFs] were studied; they underwent metabolic parameters evaluation once before the onset of hormone therapy (baseline), once after about 12 months (52.14 weeks ± 17.1 days) of hormone therapy (at year 1) and once after about 24 months (107.75 weeks ± 18.9 days) of hormone therapy (at year 2). The remaining 24 patients (16.4 %) were excluded because of their metabolic alterations (n = 14, 9.6 %) and/or because of their positive family history of metabolic alterations (n = 18, 12.3 %) which were a potential bias in studying the metabolic risks of hormone therapy. Among the excluded 24 patients with personal/family history of metabolic alterations, 8 had also a previous treated psychiatric pathology (n = 8, 5.5 %). 




Blood samples were collected after a 12-h overnight fast, one hour after wake up. Blood samples were deposited in dry tubes with EDTA. The plasma was separated immediately using refrigerated centrifugation at 2,500 –3,000 rpm for a period of 10 min. The samples were processed either immediately or during the first week after conservation at - 20°C. All the patients performed these evaluations. Blood samples in FtM patients were performed during the early follicular phase (cycle day 2, 3, 4 or 5) at baseline and halfway between two testosterone administrations at year 1 and at year 2. All tests were performed in accordance with standard procedures [47]. 
Measurement of glyco-insulinemic metabolism 
For epidemiologic and clinical studies indirect methods have been advocated for quantification of insulin resistance, based on measuring plasma insulin levels during fasting or after glucose stimulus and on the insulin-glucose ratio calculated with different mathematical formulas. The most common methods include measurement of fasting blood glucose levels (FG), fasting blood insulin levels (FI), and the homeostasis model assessment of insulin resistance (HOMA-IR) indices. FG was measured by colorimetric method while FI was measured by IRMA. HOMA-IR index was calculated as follows: FI (mU/l) × FG (mmol/l)/22.5 [48]. 
Measurement of serum lipid profile
Total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and triglycerides (TG) concentrations were measured using standard enzymatic automated methods. High density lipoprotein-cholesterol (HDL-C) levels were measured by enzymatic procedure after precipitation. An atherogenic index (AI = TC ÷ HDL-C) was calculated as indicated by the World Health Organization (WHO) [49].
Measurement of anthropometric parameters
Waist circumference, weight, height, body mass index (BMI) and blood pressure were measured at baseline, at year 1 and at year 2. Weight was measured to the nearest kilogram (kg). Height was determined to the nearest meter (m). BMI was calculated as the weight (kg) divided by the square of height (m). Systolic and diastolic blood pressure was evaluated in three consecutive occasions in the right arm with the subjects in a relaxed sitting position. For each patient, at baseline, at year 1 and at year 2, a mean of the three blood pressure measurements was calculated.
Metabolic syndrome (MetS) diagnosis
Participants were received diagnosis with MetS at follow-up if they met three or more of the defining criteria according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLB) [3, 4].

Statistical analysis
Statistical analysis was conducted using STATA 10 (Stata Corp, USA). The differences in the demographic variables between MtF and FtM patients were evaluated using independent t-tests and chi-square (or Fisher’s Exact test for 2 x 2 tables). The comparisons of FG, FI, HOMA-IR, TC, TG, LDL-C, HDL-C, AI, BMI and blood pressure (systolic and diastolic) during the hormonal treatment exposition were performed using repeated measures ANOVAs (Bonferroni-adjusted). The differences of the proportion of GD patients with and without MetS among hormonal exposition and concomitant psychiatric problems were evaluated using Cochran’s Q test, McNemar’s test (Bonferroni-adjusted) and chi-square (or Fisher’s Exact test for 2 x 2 tables). The significance level was set at p <0.05. 
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Sociodemographic information of the 122 patients with gender dysphoria included in this study (age, level of education, partnership status, living arrangement, employment status and sexual orientation) are reported in Table 1. MtFs and FtMs did not show differences in their sociodemographic characteristics. 

Metabolic changes after hormonal treatment
At enrollment, 14 subjects out of the 146 individuals evaluated for GD during a period of 5 years were excluded because of their metabolic alterations (9.6%). The prevalence of MetS among GD patients at enrollment was not significantly different from that found (13%, n = 283) in a large population-based follow-up study of healthy individuals of the same age with no history of type I diabetes or CVD, using the same methodology of our study (n = 2182; mean age: 32 ± 5 years) [50] (X2 = 1.41, p = 0.24).
Baseline metabolic parameters of MtF and FtM individuals included in this study were in the normal range, confirming that all patients were metabolically healthy at enrollment. Both at year 1 and year 2, changes in several parameters were found which are clustered in MetS, with statistically signiﬁcant differences compared to baseline (Table 2, 3). MtFs reported significant alterations in the glyco-insulinemic profile. Instead, hormonal treatment barely affected the glyco-insulinemic profile in FtMs. Hormonal treatment affected weight, waist circumference, blood pressure and the lipid profile in bothMtFs and FtMs. Moreover, glyco-insulinemic alterations, weight gain and blood pressure increase were more pronounced during the first year of cross-sex hormonal treatment. The negative effect of hormonal treatment on serum lipid profile and waist circumference, instead, increased significantly over time, both in MtFs and FtMs (Tables 2, 3). Among the enrolled sample, 18 patients at year 1 (14.8%) and 21 patients at year 2 (17.2%) developed MetS. The prevalence of MetS among the healthy subjects included in our study was not significantly different from that found in the general population [50] (year 1: X2 = 0.32, p = 0.57; year 2: X2 = 1.82, p = 0.18). However, when including in the calculation of the MetS prevalence also those subjects excluded because presenting MetS at enrollment (n = 14), the prevalence of MetS in our GD population after the beginning of the hormonal treatment (year 1: 22%, n = 32; year 1: 22%, n = 32) was significantly higher than that found in the general population [50] (year 1: X2 = 9.36, p = 0.002; year 2: X2 = 14.05, p < 0.001).    

Gender dysphoria patients’ concomitant psychiatric problems
Twenty of the 122 enrolled GD patients (16.4%; 12 MtFs, 15.2%; 8 FtMs, 18.6%) received a major axis-I psychiatric disorder diagnosis based on the DSM-IV-TR criteria. GD patients with concomitant psychiatric problems received antidepressants (n = 17, 85%; 10 MtFs, 83%; 7 FtMs, 87.5%) and/or antipsychotics (n = 14, 70%; 9 MtFs, 75%; 5 FtMs, 62.5%). They received the cross-sex hormonal treatment after 15.62 months ± 13.56 months of psychopharmacological treatment. When they received the hormonal treatment, medications  dosages and administration modalities were stable for 12.72 months ± 9.32 months. All these 20 patients continued to receive stable psychopharmacological treatment during the sex hormones administration. Concomitant psychiatric problems were not associated with any sociodemographic variable (all p > 0.1). Moreover, MtFs and FtMs did not significantly differ in their prevalence of psychiatric problems (all p > 0.1, Table 4, 5).

Mets diagnosis in hormone treated GD patients with and without concomitant psychiatric problems

















Using a longitudinal design, this 2 year follow up study aimed to assess the prevalence of cross-sex hormonal treatment induced metabolic syndrome (MetS) in a quite large sample of metabolically healthy patients with gender dysphoria. Moreover, for the first time this study evaluated the impact of concomitant psychiatric problems in the development of MetS after the beginning of the cross-sex hormonal treatment. 
Results from this study indicate that, due to the hormonal treatment, healthy GD patients develop several metabolic alterations which are clustered in MetS. Consistently with previous studies, these alterations were already reported after only one year of cross-sex hormonal treatment, in both MtFs and FtMs [12-17]. However, hormonal treatment affected the glyco-insulinemic profile mainly in MtFs, confirming that attention should be paid to the effects of oestrogens on insulin sensitivity [12-17]. 
During the two year follow-up assessment relatively few patients with GD satisfied the diagnostic criteria for MetS, both at year 1 and at year 2. Moreover, when considering only individuals without concomitant psychiatric problems, the prevalence of MetS was even lower than in the enrolled sample (7.8% vs. 14.8% at year 1, 9.8% vs. 17.2% at year 2). Instead, about one out of two GD patients with concomitant psychiatric problems developed MetS after the beginning of the cross-sex hormonal treatment, indicating that patients with GD suffering from a psychiatric disorder represent a vulnerable population to hormonal treatment related metabolic alterations.    
Another important result of this study is that MetS mostly occurred in the first year of hormonal treatment. In fact, during the second year of hormonal therapy there was only a small and not statistically significant increase in MetS prevalence, both in MtFs and FtMs and both in patients with and without concomitant psychiatric problems. These findings seem to suggest that the first year of cross-sex hormonal treatment represents a critical period with deserves particular clinical attention. However, data are too limited to be conclusive.
MetS has been identified as an important health risk in the management of psychiatric disorders [51-55]. Specifically, several studies indicate that patients with mental disorders have a shorter life expectancy and that the increased mortality should be attributed to the higher prevalence of MetS related CVD [26, 27]. Consistently, while in this study cross-sex hormonal treatment resulted to be associated with a relatively lowly onset of MetS, MetS development in GD patients who had concomitant psychiatric problems was considerably high and significantly greater compared to remaining individuals.
Psychopharmacological treatments and several environmental and genetic factors, alone or in combination, are involved in the increased MetS and related health problems among patients suffering from concomitant psychiatric problems[28-41]. In particular, the increasing use of second generation antipsychotics (SGAs, i.e. olanzapine, clozapine) or ‘atypicals’ has run parallel with the increasing recognition of excessive body weight gain and MetS in psychiatric practice [36, 37, 39, 41]. In the same way, many antidepressant medications (Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors (SSRI)] have also been associated with higher BMI and waist circumference, with possible etiologies involving variable and complex interactions with neurotransmitter pathways [38, 40]. As in this study all the GD patients were metabolically healthy at enrollment, we can suppose a direct role of the psychopharmacological treatment in the increased MetS among GD patients suffering from concomitant psychiatric problems. However, we can not exclude the role of other environmental or genetic factors in mediating the psychopharmacological treatment side effects on GD patients’ metabolism. 
Results from this study have important public health implications. Identification, prevention, and modification of the cardiovascular risk factors should be one of the important therapeutic objectives among hormone treated patients with GD, especially if suffering from a psychiatric disorder. For instance, transdermal oestradiol administration is recommended in MtF individuals, particularly in the population over 40 years in whom a high incidence of venous thromboembolism has been observed with oral oestrogens 56]. Oral and transdermal oestrogens administrations seem to affect lipid profile differently 14]. Further studies are needed to assess possible differences in hormonal treatment induced metabolic alterations among MtF individuals due to type and route of estrogens administration. Our findings emphasize the need for regular clinical and laboratory tests from the beginning of the hormonal treatment intervention. Even if in our study no patient developed cardiovascular events or other medical morbidities, the observed metabolic changes induced by cross-sex hormone therapy in a short term period should be considered in terms of preventive medicine and primary prophylaxis. The goal might be to minimize as much as possible any side effects of cross-sex hormone therapy, especially in the context of concomitant psychiatric problems, considering that hormonal treatment, and often also psychopharmacological treatment, must be continued for a long period of time. This could increase the risk of developing MetS and related comorbidites. 
Gender-specific reference intervals for MetS diagnosis raised the dilemma of deciding what criteria are appropriate for GD patients. It is well established that gender related differences in fat distribution and especially in visceral adiposity partially explain the difference in CVD risk between males and females 57]. Even if MtF and FtM patients progressively invert their fat distribution after the beginning of the hormonal treatment, tending to those of the desired gender, visceral fat is marginally affected 57]. For these reasons and also considering that our study included GD adults with a relatively short-term follow-up, we considered the natal gender related CVD risk. As recently suggested, it is still not clear which reference interval is appropriate for the majority of the laboratory results, including metabolic parameters, indicating that new reference intervals need to be established for GD patients 58]. 
  Our results should be considered in light of some limitations. This study used a clinical sample and the prescription of psychiatric medications was based on the individual treating psychiatrist’s decision rather than on randomization or specific psychopharmacological treatment related hypothesis. Therefore, also because of the small sample size of the patients with GD suffering from a psychiatric disorder, in this study it was not possible to evaluate the distinctive role of specific psychiatric disorders or specific medications and dosages in the association between cross-sex hormonal treatment and MetS. Moreover, even if we adopted some inclusion criteria in order to exclude a potential lifestyle related bias, and health assessments were conducted during the follow-up, we cannot exclude a confounding effect of lifestyle on hormonal treatment induced MetS. Further researches are needed to improve these issues. However, this is the first study considering concomitant psychiatric problems and related use of psychopharmacological medications in the association between cross-sex hormonal treatment and MetS in individuals with gender dysphoria. Moreover, this study enrolled a large group of metabolically healthy patients, excluding the presence of personal or family history of metabolic alterations which could be a very important bias.
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